Filters
reset allTests names and labs | Conditions | Genes, analytes, and microbes | Methods |
---|---|---|---|
PEX1 - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 3 | 1 |
|
Carrier Screening Guidelines-Based Panel Ambry Genetics United States | 199 | 165 |
|
Centogene AG - the Rare Disease Company Germany | 498 | 498 |
|
Centogene AG - the Rare Disease Company Germany | 499 | 499 |
|
Invitae Comprehensive Neurometabolic Disorders Panel Invitae United States | 351 | 249 |
|
Invitae United States | 32 | 17 |
|
PreventionGenetics United States | 130 | 69 |
|
Non-Immune Hydrops Fetalis Panel PreventionGenetics United States | 291 | 148 |
|
Lysosomal Storage Disorders Panel PreventionGenetics United States | 242 | 146 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Invitae Metabolic Non-Immune Fetal Hydrops Panel Invitae United States | 50 | 51 |
|
Invitae Inherited Retinal Disorders Panel Invitae United States | 486 | 293 |
|
Invitae Broad Carrier Screen without X-linked Disorders Invitae United States | 195 | 98 |
|
Invitae United States | 224 | 112 |
|
Invitae Comprehensive Carrier Screen Invitae United States | 886 | 547 |
|
PEX1-Related Zellweger Syndrome Spectrum Myriad Genetics, Inc. United States | 2 | 1 |
|
Parkinson Disease and Parkinsonism Panel PreventionGenetics United States | 68 | 70 |
|
Invitae Treatable Neurometabolic Disorders Panel Invitae United States | 257 | 191 |
|
Invitae Zellweger Spectrum Disorder Panel Invitae United States | 36 | 18 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.